Transaction · 0001817217-26-000016

Van Houte Hans

van Houte Hans, CFO, reported an open-market or private sale at Nurix Therapeutics, Inc. involving 1469.000000 shares for an estimated $23800.44. Reported holdings after the transaction were 42745.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
NRIXNurix Therapeutics, Inc.
Trade date
Nov 04, 2026
Filing date
Nov 04, 2026
View on SEC Insider profile
Disclosed value-$23.8kShares × reported price
Shares traded1.46k$16.20 per share
Holdings after42.7kDirect
% of reported position traded3.32%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 44,214 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

NRIX price since this filing

Daily closing prices, with the filing date and available return windows
NRIX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +43.4%1w ago +70.9%1d ago +61.9%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001817217-26-000016
Common Stock
Transaction date
Nov 04, 2026
Filed Nov 04, 2026, 10:05 PM · 0d delay
Shares
1,469 sh
$16.20 per share
Estimated value
-$23.8k
Computed from shares × price
Holdings after
42,745 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

  2. F2

    Represents the weighted average sale price. The lowest price at which shares were sold was $14.91 and the highest price at which shares were sold was $15.89. The Reporting Person undertakes to provide…

  3. F3

    Represents the weighted average sale price. The lowest price at which shares were sold was $15.91 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide…

Original filing · 0001817217-26-000016
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

NRIX